Purpose: To assess the risk and benefit of pars plana vitrectomy for diabetic macular edema. Methods: The authors conducted a systematic literature review using PubMed, EMBASE, Web of Science, and Cochrane Central Database of Controlled Trials until September 2014. The population was patients with diabetic macular edema, intervention vitrectomy, comparator macular laser or observation, and efficacy outcome visual acuity and central retinal thickness. Safety outcomes were intraoperative and postoperative surgical complications. The efficacy meta-analysis included only randomized controlled trials. The safety analysis included prospective, retrospective, controlled, and uncontrolled studies.
D
iabetic macular edema (DME) is a leading cause of visual loss in developed nations, 1, 2 and as the population with diabetes expands, 3 the burden of DME will increase. For many years the standard therapy for DME has been focal macular photocoagulation laser. The Early Treatment of Diabetic Retinopathy Study established that laser approximately halves the risk of moderate vision loss in patients with clinically significant macular edema. 4 More recently, several randomized controlled trials (RCTs) have demonstrated the safety and efficacy of intravitreal steroid injections and implants. [5] [6] [7] [8] [9] Vascular endothelial growth factor (VEGF), by increasing vascular permeability, plays an important role in the pathogenesis of DME. 10, 11 Studies investigating the intravitreal use of the anti-VEGF agents ranibizumab, [12] [13] [14] [15] [16] aflibercept, 2, 17 and bevacizumab 18 have also shown favorable results. 19 There are a number of clinical studies suggesting that an attached vitreous may adversely affect the clinical course of DME, or possibly contribute to its pathogenesis. Sivaprasad et al 20 found that posterior vitreous detachment was less common in eyes with DME, and that vitreous attachment seemed to reduce the benefit of intravitreal steroid therapy. A synthesis of the literature by Jackson et al 21 found that some degree of vitreomacular traction (VMT) was present in 12% of eyes with DME, and up to 24% in surgical series. Vitreomacular traction may aggravate any underlying tendency for DME, and if severe, VMT can cause macular edema in its own right. It therefore seems reasonable to assume that relief of VMT would be beneficial.
Several authors have advocated the use of pars plana vitrectomy (PPV) to treat DME. Although PPV is well established for the treatment of persistent vitreous hemorrhage 22 and tractional retinal detachment, 23, 24 its use as a treatment for DME has not been supported by large RCTs.
Laboratory studies provide a theoretical basis to support the use of PPV. Several animal studies [25] [26] [27] and some human studies 28 reported that PPV increases vitreous oxygenation in the context of ischemia, and increased oxygen tension is likely to reduce VEGF. It has been estimated that vitreous viscosity is 300 to 2,000 times greater than aqueous, 29 and after vitrectomy diffusion coefficients of intravitreal molecules, including VEGF, should increase by a similar magnitude. 30 Therefore, after PPV, VEGF, and other proinflammatory cytokines would be expected to diffuse away from the macula more easily. 31 Conversely, the postvitrectomy decrease in the viscosity of the vitreous cavity has the possible disadvantage of interfering with intraocular pharmacokinetics and reducing the half-life of intravitreal drugs. 32 In the absence of large RCTs of PPV for DME, we aimed to undertake a systematic review and metaanalysis to assess if PPV is an appropriate surgical intervention. Specifically, we aimed to determine the benefit of PPV in terms of the mean change in visual acuity (VA) and reduction in optical coherence tomography (OCT) central retinal thickness (CRT), and the risk in terms of intraoperative and postoperative complications. An analysis of risk and benefit is particularly important in the context of new intravitreal drug treatments that have proven efficacy and favorable safety profiles-interventions that do not expose patients to the risks of PPV.
Methods
Study Design, Population, Intervention, Comparison, and Outcome
We aimed to estimate the risk and benefit of PPV for DME. To estimate the potential benefit of PPV, we used a meta-analysis of efficacy outcomes, selecting only RCTs. To estimate the risks of PPV, in terms of surgical complications, we undertook a systematic review, to encompass a wider range of literature and increase the likelihood of detecting rare events. The population was patients with DME, the intervention was PPV, and the comparison was traditional standard care, 4 namely focal macular photocoagulation laser or observation. The two main efficacy outcomes were VA and OCT CRT. Safety outcomes included all reported intraoperative or postoperative surgical complications, or other adverse events attributed to PPV or local or general anesthesia. The study protocol was registered with the international prospective register of systematic reviews (registration number CRD42014013646, National Institute of Health Research Centre for Reviews and Dissemination, University of York, UK) and conducted in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRIS-MA) guidance (http://www.prisma-statement.org/, accessed 21 January 2015).
Eligibility
To be eligible for the meta-analysis, RCTs had to recruit patients with DME, and compare PPV to traditional standard care (observation or macular photocoagulation laser) for the treatment of DME. Outcome data had to include change in VA and change in CRT at least 6 months after enrollment, and safety at any time point. The data had to be of sufficient quality, in terms of clear eligibility, defined efficacy and safety outcomes, and data completeness, and in particular, studies had to report any complications that occurred, or state that there were none. Only English, French, and German language articles in peer-reviewed journals were eligible. Studies that failed to provide preoperative and postoperative VA were excluded, as were those appearing as abstract only, and studies where patients received adjunctive therapy such as intravitreal steroids and anti-VEGF drugs, as these could confound the analysis of vitrectomy versus laser/ observation. Editorials, expert opinions, and articles in non-peer-reviewed journals were excluded. Articles using intravitreal vital stains to assist with peeling of the internal limiting membrane were not excluded. [33] [34] [35] [36] Similar eligibility criteria were applied to the safety analysis, except that studies did not need to be RCTs or have a control group, the minimum VA follow-up did not apply, and they need not report CRT. Prospective, retrospective, controlled, and uncontrolled studies, including case reports, were eligible for the safety analysis.
Literature Review
An Ovid MEDLINE database search from 1946 to 23 September 2014 was undertaken using Boolean operators with the following keywords (and corresponding MESH headings if they were available): vitrectomy; diab*; macula*; oedema or edema; maculopathy; VMT; vitreomacular adhesion; and taut posterior hyaloid. The search was not restricted by adding terms such as adverse events, complications, or safety, but rather each eligible article was reviewed for safety data. Searches were repeated using EMBASE (Ovid), and the Cochrane Central Database of Controlled Trials (CENTRAL, Cochrane library). An example search is shown in eAppendix 1 (see Supplement Digital Content 1, http:// links.lww.com/IAE/A517).
The retrieved abstracts were then reviewed by two senior retinal experts (TJ, EP) who selected articles for full review if they seemed to meet the eligibility criteria. Further articles were identified in the bibliographies of retrieved articles. Where necessary, authors were contacted to obtain unpublished raw data from RCTs.
Data Extraction
Three independent reviewers (FG, AA, EN) entered data from each article into an electronic data capture form. Any discrepancy was resolved by consensus or, if necessary, by arbitration of a senior retinal specialist (TJ). The protocol for data collection included the following information for each article: 1) general information about the study (aim, summary, key findings); 2) methodological details (study design, study population, entry criteria, methods, study period); 3) primary and secondary outcomes; 4) presenting and final VA; 5) whether or not eyes underwent peeling of the internal limiting membrane at the time of PPV; and 6) safety outcomes (adverse events and serious adverse events, including surgical complications and reoperations).
Assessment of Bias
The risk of bias was assessed using the Cochrane Risk of Bias Assessment tool which grades risk of bias as low, unclear, or high risk. Seven domains of risk were assessed including assessments for selection bias, performance bias, detection bias, attrition bias, and reporting bias.
Data Analysis
To analyze visual outcome across studies, the mean VA data were converted to logarithm of the minimum angle of resolution (LogMAR) units. 37 Counting fingers vision was assigned a LogMAR acuity of 1.6, hand movements 1.9, light perception 2.2, and no light perception 2.5. [38] [39] [40] Meta-analysis was used for pooled comparisons of the mean change in LogMAR VA and change in CRT comparing PPV and control (observation or laser). The fixed-effect method with inverse variance weighting was used. Statistical analysis was performed using RevMan 5.2 available from the Cochrane Collaboration. 41 Safety data were pooled across all studies, including non-RCTs.
Results

Meta-analysis of Efficacy
Six RCTs were identified that provided mean change in LogMAR VA and mean change in retinal thickness, comparing patients having undergone PPV with controls. [42] [43] [44] [45] [46] [47] One study was excluded, because it was not possible to obtain raw data or summary statistics for the outcomes in question, despite contacting the author (see eAppendix 2, Supplemental Digital Content 2, http:// links.lww.com/IAE/A518). 47 Additional, anonymous participant-level data were obtained from two study authors, such that their reports could be included in the meta-analysis. 45, 46 Of the five RCTs included, four used a laser control group 42, 43, 45, 46 and one used an untreated control group. 44 We identified possible duplicate reporting in two studies, 43, 44 but concluded these were different populations given the different eligibility criteria and control groups. Follow-up duration was 6 months in 3 studies 42, 44, 46 and 12 months 45, 46 in 2 (one study reported both outcomes 46 ) ( Table 1) . One study 46 reported results at 6 and 12 months, where 5 patients were double counted for the LogMAR results and 6 patients for the CRT. Sensitivity analysis was performed to test the effect on the results by excluding the 6 months or 12 months outcome. This resulted in similar magnitude and precision of results. We preferred to report the combined results (at 6 and 12 months) because of the greater sample size. This summarizing error was considered acceptable as sensitivity analysis testing showed it did not affect the conclusion.
All RCTs seemed to be at low risk of reporting bias ( Figure 1, A and B) . It is not possible to effectively mask patients to the intervention, vitrectomy, and as such, all studies are at risk of introducing performance bias. Detection bias may have been minimized using masked assessors for VA outcome collection, although only 2 of 5 studies explicitly stated doing this. 44, 48 It was felt that the collection of automated OCT CRT data was unlikely to introduce bias whether masked assessors were used or not. Randomization methodology and allocation concealment were not always explicitly reported across the trials (see eAppendix 3, Supplemental Digital Content 3, http://links.lww.com/IAE/A519). Figure 2 shows a forest plot of the vision outcome (mean change in VA in LogMAR units) from the meta-analysis of the five RCTs, comparing PPV with control. Overall, there was a 2 letter (0.04 logMAR units) difference favoring PPV over control, but this was not significant (95% CI 20.02 to 0.1 logMAR units, P = 0.18).
As part of the iterative process and in accordance with PRISMA guidance, the original analysis protocol was adapted to accommodate the variability in the follow-up interval reported (6 or 12 months) and control group (observation or laser). Specifically, we undertook a post hoc analysis of the main efficacy outcome measures (change in mean VA and CRT) in three subgroups: 1) studies reporting outcomes at 6 months with laser control; 2) studies reporting at 12 months with laser control; and 3) studies reporting at 12 months with untreated controls. In the laser Fig. 1 . Risk of bias summary and graph. Figure 1 illustrates the risk of bias summary (A) and the risk of bias graph (B). The review is based on the authors' judgments about each risk of bias item for each included study. The risk of bias in each article was evaluated for across seven domains. Each domain was rated as either low risk, unclear risk, or high risk of introducing bias. +, low risk; ?, unclear risk; -, high risk. Fig. 2 . Meta-analysis of vision outcome comparing PPV to standard care. Figure 2 shows a meta-analysis of vision outcome (change in mean logarithm of the minimum angle of visual acuity), comparing PPV to standard care (observation or macular laser). The overall analysis of the five RCTs showed a better visual outcome in the vitrectomy group, but this was not quite significant and there was heterogeneity among the trials. IV, inverse variance method used; Fixed, fixed effect model used.
controlled studies, using mean VA at 6 months, there was an almost significant (P = 0.05) benefit from vitrectomy compared with laser, however, this reversed at 12 months, with an almost significant result favoring laser (P = 0.07). The subgroup analyses are shown in Figure 2 . Within each subgroup the results were similar, however, on combining all 3 subgroups, there was moderate heterogeneity (I 2 of 60%). Figure 3 presents a forest plot of the meta-analysis of the same five RCTs, with respect to change in CRT. Overall, there was a significant, 102 mm (95% CI 61-144 mm, P , 0.00001) greater reduction in macular thickness in the pooled vitrectomy group compared with the control group (I 2 of 78%). However, as can be seen in Figure 3 , the subgroup analysis suggested that the advantage of PPV over laser at 6 months was not evident at 12 months.
Safety
A total of 425 abstracts were retrieved. Of these, 106 potentially eligible articles were reviewed in full, of which, 40 were eligible for the safety analysis. Although the literature search extended back to 1946, the first eligible report was published in 1992, 3 and 38 of 40 were published after 2000 (see eAppendix 4, Supplemental Digital Content 4, http://links.lww. com/IAE/A520).
In 40 studies, intraoperative and postoperative complications were reported (Table 2) . 3, [42] [43] [44] 46, The most frequent intraoperative surgical complications were peripheral retinal break (7.08% of 1,469 eyes), iatrogenic tears (0.68% of 1,469 eyes), and focal, petechial spontaneously resolving retinal hemorrhage (0.34% of 1,469 eyes). The most frequent postoperative complications were raised intraocular pressure (5.19% of 1,562 eyes), epiretinal membrane (3.27% of 1,562 eyes), vitreous hemorrhage (2.43% of 1,562 eyes), neovascular glaucoma (1.60% of 1,562 eyes), glaucoma (1.41% of 1,562 eyes), macular hard exudates (1.34% of 1,562 eyes), and retinal detachment (1.22% of 1,562 eyes) .
The rate of postvitrectomy cataract was not reliably reported and many reports did not detail the proportion of phakic eyes. Cataract was reported to develop in only 40 of 1,562 eyes (2.56%), of which 47.5% (19 of 40 eyes) underwent subsequent cataract surgery. Four studies provided the postvitrectomy cataract rate in 121 phakic eyes, and 83 (68.6%) of these eyes developed cataract over a mean of 31.0 months. 57, 65, 67, 70 A post hoc safety analysis was undertaken using the data from the RCTs included in the efficacy metaanalysis, to assess if the complication rates differed from those reported in the main safety analysis (which included uncontrolled and retrospective studies). The complication rates seemed similar in the 46 participants with detailed safety reporting, in that the most common complication was progression of nuclear sclerosis (23.9%) followed by raised intraocular pressure (6.5%). The only other complication reported was rhegmantogenous retinal detachment in one patient (2.1%). [42] [43] [44] 46 Fig . 3 . Meta-analysis of change in OCT macular thickness comparing PPV to standard care. Figure 3 presents a meta-analysis of change in OCT macular thickness, comparing PPV or standard care (observation or macular laser). The overall analysis showed that vitrectomy resulted in a significantly greater reduction in macular thickness than standard care. IV, inverse variance method used; Fixed, fixed effect model used.
Discussion
Our meta-analysis of RCTs suggests that the visual benefits after vitrectomy for DME were not significantly better than those achieved using conventional management with laser and observation. The RCTs indicated that PPV was associated with a significantly greater reduction in macular thickness than laser and observation, but there was heterogeneity in this overall result, and our subgroup analysis may be more informative. This showed a trend for better OCT results than with laser at 6 months, but this trend had reversed by 12 months.
The VA gain in the RCTs was equivalent to 2 Early Treatment of Diabetic Retinopathy Study letters (0.04 LogMAR). The Ranibizumab for Edema of the mAcula in Diabetes study randomized patients with DME to receive ranibizumab, macular laser, or both. 14 In the group receiving only ranibizumab, vision improved by an average of 7.4 letters at 6 months. Another RCT compared ranibizumab alone, and in combination with macular laser, and reported a mean gain of 6.1 letters at 12 months in the group that only received ranibizumab. 15 Yet another study showed a 5.8 letter gain after ranibizumab and deferred laser. 16 As such, the PPV RCT results do not compare favorably with those of anti-VEGF therapy in terms of the mean VA change (or in relation to the comparison with a laser control group). However, direct comparison between the anti-VEGF studies and our metaanalysis is difficult for several reasons. Key among these is that vitrectomy is often reserved for patients who have failed other treatments, whereas anti-VEGF agents are often used as a first-line treatment. Ideally, there would be RCTs directly comparing PPV and anti-VEGF treatments.
No major safety concerns were identified. Retinal breaks were the most common complication. A database study of 8,257 PPVs also found that retinal breaks were the most common intraoperative complication. 83 In the subset of eyes undergoing epiretinal membrane surgery, a PPV of similar complexity, iatrogenic retinal breaks occurred in 3.0% of cases, whereas the present series incorporated studies that used somewhat varying terminology, with those describing "peripheral retinal breaks" averaging a 7.1% rate, and those reporting "iatrogenic tears" averaging 0.7%. Retinal detachment occurred in 1.5% of the epiretinal membrane cases, compared with 1.2% in the present analysis. The incidence of postvitrectomy hemorrhage and neovascular glaucoma was higher in the present series, consistent with an underlying diagnosis of diabetes. Although the safety of PPV for DME seems comparable to other studies of PPV, the complication rates are higher than those seen after intravitreal anti-VEGF injections for DME. 13, 15, 16 The main strength of the present meta-analysis is that it provides a pooled estimate of treatment effect across several RCTs, and the safety analysis considers an even larger pool of patients that may be better able to detect rare events. There is a risk that publication or reporting bias may favor the selection of reports describing positive surgical outcomes. 84, 85 Also, postvitrectomy lens changes may be a confounding variable. It was not possible to determine the lens status in many studies, or to reliably determine the proportion of eyes that underwent cataract surgery. It is well known that PPV causes cataract, and this is likely to reduce the mean visual gain, and this is possibly suggested by the worse VA outcome at 12 months compared with 6 months, as shown in Figure 2 (this would not however explain a worsening of the OCT outcome over this time frame). Conversely, removal of preexisting lens opacity during initial combined phakovitrectomy, or subsequently as a result of postvitrectomy cataract, will tend to improve the mean VA of the PPV group. Although laser or observation remains the standard of care for many patients, anti-VEGF therapy is now emerging as a standard of care for many other patients. Our results suggest that PPV is not superior to laser or observation, and the pivotal anti-VEGF trials in turn show that anti-VEGF treatment is superior to laser; this might seem to indicate that anti-VEGF therapy is superior to PPV, but that analysis requires direct comparison of PPV versus anti-VEGF therapy, and is not proven by our analysis.
Another intrinsic difficulty of studies involving PPV is that masking is not possible, because sham surgery would not be practical. However, most of the RCTs provided relatively robust VA assessment, and lack of masking is unlikely to materially influence CRT measurement, which relies on automated computer software analysis.
Interventional case series recruit patients in whom surgery is considered clinically reasonable, and those with milder disease may have been excluded. 86 Therefore, the results may not be representative of all patients with DME, or comparable with studies investigating intravitreal injections. Also, even if the overall functional benefit was no better than macular laser, it is possible that a subgroup of patients with DME and significant VMT may benefit from PPV. Vitreomacular traction or taut posterior hyaloid is reported to be present in 17% of DME cases undergoing PPV. 21 In summary, this study found that PPV produced both structural and functional benefit in eyes with DME, but the functional benefit was not significantly better than that obtained using macular laser, and the structural benefits seemed to decline, or possibly reverse, with time. Like previous reviews, 21 we identified a lack of high-quality evidence, and the need for large RCTs comparing PPV to the latest gold standard, in particular intravitreal anti-VEGF drugs. Given the favorable results with these newer treatments, the need to justify PPV becomes even greater.
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